Eveliqure
3 known investors
Find your way into Eveliqure
Eveliqure develops a live attenuated vaccine platform for oral administration targeting Shigella and ETEC pathogens that cause diarrheal disease in travelers and populations in low- and middle-income countries. The company's lead product, ShigETEC, provides broad serotype-independent protection against multiple pathogens through targeted genetic mutations.
Also known as EveliQure Biotechnologies · Eveliqure Biotechnologies GmbH
Founders & leadership
Investors · 3
Company profile
researched Aug 2026Eveliqure Biotechnologies GmbH is a Vienna, Austria-based clinical-stage biotechnology company developing vaccines to prevent diarrhoeal diseases in travellers and in people living in endemic regions of low- and middle-income countries. Its technology platform is built on a live attenuated strain of the bacterium Shigella that has been engineered to induce broad protection across different species and serotypes of the pathogen, and into which non-Shigella antigens can be introduced to extend protection to additional pathogens.
The company's first-generation candidate, ShigETEC, is an oral live attenuated vaccine derived from an engineered Shigella strain that lacks the ability to invade gut epithelial cells, removing a key virulence feature of shigellosis. Highly variable surface sugar antigens have been deleted with the aim of eliciting broad-spectrum Shigella immunity, and the strain expresses enterotoxigenic Escherichia coli (ETEC) toxoid antigens intended to induce antibodies that neutralise diarrhoeagenic toxins. No licensed vaccines exist against Shigella or ETEC, which together account for roughly 200 million diarrhoea cases annually in children under five.
The company name combines 'Endovelicus', the Celtic god of public health, with the word 'liquid', a reference to a drinkable vaccine.
Business model
Eveliqure develops vaccine candidates in-house and monetises them through licensing and partnership agreements with manufacturers and commercialisation partners, while retaining selected market rights for itself. Under its agreement with Serum Institute of India, SII holds non-exclusive global rights to ShigETEC for paediatric populations and leads development and global commercialisation, while Eveliqure retains rights to the traveller and military markets and can pursue further collaborations in those fields.
Revenue sources include a one-time upfront fee, development, regulatory and commercial milestone payments, and royalties on net sales under the Serum Institute of India licence agreement, alongside non-dilutive public grant and government contract funding (FFG, Austria Wirtschaftsservice, NIAID contract, Horizon 2020 consortium grant).
Traction
ShigETEC completed a Phase 1a tolerability and immunogenicity study in European adults (NCT05409196) and a Phase 1b tolerability, dose-finding and immunogenicity study in Bangladesh (NCT05987488) conducted with icddr,b across age groups including infants aged 6-11 months, which recently finished with data analysis underway. A Phase 2b controlled human infection model study in the United States (NCT07049159) at Johns Hopkins University in Baltimore is enrolling healthy, Shigella-naive adults, with results expected in 2026. The company was ranked the fastest-growing alumni-led business in the University at Buffalo's Fast 46 competition in September 2022, a ranking based on verified revenue growth over three years of financial data.
Latest developments
In March 2026, Eveliqure and Serum Institute of India announced a strategic collaboration and licence agreement covering development, manufacturing and commercialisation of anti-diarrhoeal vaccines, granting SII non-exclusive global rights to ShigETEC for paediatric populations. The Phase 1b paediatric study in Bangladesh recently concluded with data analysis underway, and the ongoing Phase 2b CHIM study in the US is expected to report in 2026.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Eveliqure operates in an area with no currently licensed vaccines against Shigella or ETEC, the two most prevalent bacterial pathogens causing diarrhoea in children under five, a gap compounded by the spread of multi-drug resistant Shigella strains. Its partner, Serum Institute of India, is described as the world's largest vaccine manufacturer with a presence in more than 170 countries.
The candidate is an oral live attenuated vaccine that combines broad-spectrum Shigella coverage, achieved by deleting variable surface sugar antigens and the epithelial-cell invasion capability, with ETEC toxoid expression in a single strain, addressing two major diarrhoeal pathogens simultaneously. The underlying platform also allows insertion of antigens from other pathogens.
Technology
A vaccine technology platform based on a live attenuated Shigella strain engineered to lack the ability to invade gut epithelial cells and to lack highly variable surface sugar antigens, intended to produce broad cross-serotype Shigella protection. The strain can be engineered to express non-Shigella antigens; in ShigETEC it expresses ETEC toxoid antigens for protection against enterotoxigenic E. coli toxins. The vaccine is administered orally as a drinkable formulation.
Go-to-market
Development is advanced through publicly funded consortia and government contracts (SHIGETECVAX/Horizon 2020, NIAID) and clinical collaborations with academic and research partners including the University of Gothenburg, icddr,b in Dhaka, PATH and Johns Hopkins University. Commercial access for paediatric populations is routed through a licence and development collaboration with Serum Institute of India, which leads manufacturing, development and global commercialisation.
Children in low- and middle-income endemic countries (the paediatric segment addressed through Serum Institute of India), plus travellers, deployed military units and disaster response personnel, markets Eveliqure retains for itself.
Geography
Headquartered in Vienna, Austria (Karl-Farkas-Gasse 22, 1030 Vienna), located at the Vienna BioCenter. Clinical and development activities extend to Bangladesh (Dhaka, with icddr,b), the United States (Johns Hopkins University, Baltimore) and Europe, with a partnership reaching Pune, India through Serum Institute of India.
History
Eveliqure developed a vaccine technology platform based on an engineered live attenuated Shigella strain and advanced its first candidate, ShigETEC, into clinical testing. It secured Austrian public research funding, a US NIAID contract with an intent to fund development through Phase 2, and participation in the EU Horizon 2020-funded SHIGETECVAX consortium. It was recognised by the University at Buffalo in September 2022 as the fastest-growing alumni-led business in its Fast 46 competition. Clinical development progressed from a Phase 1a study in European adults to a Phase 1b paediatric study in Bangladesh and a Phase 2b controlled human infection model study in the US, and in March 2026 the company entered a licence and development collaboration with Serum Institute of India.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 7
launches, deals, and filingsEveliqure was awarded an FFG Basis Grant of EUR 2.6 million from the Austrian Research Promotion Agency and EUR 190,000 from Austria Wirtschaftsservice.
Eveliqure is part of the SHIGETECVAX consortium (European Vaccine Initiative as leader, Eveliqure Biotechnologies, University of Gothenburg, icddr,b and PATH), which received a EUR 8.6 million grant over five years under EU Horizon 2020 grant agreement No 815568 for manufacture and formulation of clinical trial material and Phase 1 safety and immunogenicity studies of ShigETEC in adults in Europe and adults and children in Bangladesh.
US government contract awarded to Eveliqure by the National Institute of Allergy and Infectious Diseases with the intent to fund development of ShigETEC through Phase 2 clinical testing; base award of $215,093 with a total contract value of $20.6 million. The contract funds the Phase 2b study at Johns Hopkins University.
$20.6M source ↗
A Phase 1b tolerability, dose-finding and immunogenicity study (NCT05987488) conducted with icddr,b in Dhaka across different age groups, including infants aged 6-11 months, recently finished, with data analysis underway. It followed completion of a Phase 1a study (NCT05409196) in European adults.
Eveliqure and Serum Institute of India announced a strategic collaboration and licence agreement for the development, manufacturing and commercialisation of novel anti-diarrhoeal vaccines. SII obtains non-exclusive global rights to ShigETEC for paediatric populations and leads development and global commercialisation; Eveliqure receives a one-time upfront fee, development, regulatory and commercial milestone payments and royalties on net sales, and retains rights to the traveller and military markets.
An ongoing Phase 2b CHIM study (NCT07049159) in healthy, Shigella-naive adults is being conducted at Johns Hopkins University in Baltimore, Maryland, funded by NIAID, with results expected in 2026. The company's website announced dosing of the first participants in a Phase 2b study of the ShigETEC vaccine in shigellosis.
The University at Buffalo named Eveliqure Biotechnologies, led by Gábor Somogyi (MBA '03), the fastest-growing business owned or led by a UB alumnus or former student, based on analysis of three years of financial data by verification firm The Bonadio Group. More than 350 companies were nominated and 46 were finalists.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 7
primary sources listed
- Financing | Eveliqure Biotechnologies | Austriaeveliqure.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Eveliqure do?
- Austrian clinical-stage biotech developing oral live attenuated vaccines against Shigella and ETEC diarrhoeal disease.
- Who founded Eveliqure?
- Eveliqure was founded by Tamás Henics.
- Who are Eveliqure's investors?
- Eveliqure's investors include Kinled Holding, SmartWare.tech, STRT.